A team of researchers at the University of South Carolina (USC) created Vaccines to prevent hospital-acquired infectionscaused by drug-resistant pathogens.
In the first study, the drug was administered to mice, and Shows immune cells remain vigilant to such contaminants after dosewhich will reduce the threat to public health.
Today, most infections are caused by Staphylococcus aureus (methicillin-resistant) or Acinetobacter baumannii. Bacteria are spread through contaminated surfaces or equipment, such as catheters or respirators, or from person to person, often through contaminated hands.
In the intensive care unit (ICU), patients are at higher risk. People can suffer surgical site infections, bloodstream infections, urinary tract infections and pneumonia associated with ventilator use.
According to Kitty van Weezenbeek, Director of Antimicrobial Resistance Surveillance, Prevention and Control at the World Health Organization, “1.3 million people died from this cause globally in 2019. This number is higher than the number of deaths from HIV, malaria and tuberculosis combined. .”
In 2019, 1.3 million people died from it worldwide. This number is higher than the number of deaths from HIV, malaria and tuberculosis combined.
As a result, the team is hopeful but still cautious about the advances their findings might bring. “Even if such a vaccine existed, multiple vaccines would have to be deployed simultaneously to protect against a variety of microorganisms.”Brian Luna, associate professor of molecular microbiology and immunology at the Keck School of Medicine of USC, said:
In the study published in the journal Science, the authors listed a list of hospital-acquired infections for which the vaccine may provide protection: “We developed a non-toxic vaccine composed of aluminum hydroxide, monophosphoryl lipid A, and fungal mannan. protein vaccine, Improved survival and reduced bacterial load in mice with invasive blood or lung infections caused staphylococcus Methicillin-resistant Staphylococcus aureus Enterococcus faecalis Resistant to vancomycin, E. coli Expression profiling of beta-lactamase and carbapenem-resistant strains Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa“.
Additionally, they explain “it protects against fungus Rhizopus delbrueckii and Candida albicanss”, and “The vaccine takes effect within 24 hours after a single dose and lasts for up to 28 days, the second dose restored the efficacy. “